These adaptation mechanisms may serve as potential target for glioma therapy and suggest that β-oxidation inhibitors and probably lysosomal inhibitors (Figure 5A) may potentiate the effect of PARP inhibition in glioblastoma, and contribute to increase life expectancy in the patients of this malignant disease. Here, PARP1 is linked to central nervous system cancer.